Wilson Sonsini Advises Iterative Scopes on $150 Million Series B Funding
- Client Highlights
- Life Sciences
- Medical Devices
On January 19, 2022, Iterative Scopes, a pioneer in the development of precision-based gastrointestinal (GI) disease technologies and software, announced that it has raised $150 million in Series B financing to accelerate development of its core algorithmic innovations that are designed to transform gastroenterology care for patients. The round was co-led by Insight Partners and Clearlake Capital Group, L.P. (together with certain of its affiliates, “Clearlake”), as well as by returning investors Obvious Ventures, Johnson and Johnson Innovation-JJDC Inc., Eli Lilly, Breyer Capital, and other industry and financial leaders. Wilson Sonsini Goodrich & Rosati advised Iterative Scopes on the transaction.
The new funding will allow Iterative Scopes to speed up development of AI technology products and services by scaling the company’s technical and clinical operations teams and supporting broad applications for the company’s computational/AI-driven software solutions.